IL13RA2 and glioma: In immunodeficient mice bearing subcutaneous glioma tumors, anti-IL-13Rα2(scFv)-PE38 demonstrated significant antitumor activity with a MTD of 200 mg/kg when given intraperitoneally twice daily for 5 days.